Pro 2012-005 (Announcement of Resolutions of the 4th Session of the 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2012-005
浙江尖峰集团股份有限公司八届四次董事会决议暨召开2011年年度股东大会的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
二〇一二年三月二十六日,浙江尖峰集团股份有限公司以传真、电子邮件及专人送达的方式发出了召开第八届董事会第四次会议的通知。二〇一二年四月六日,会议如期在浙江金华尖峰大厦会议室召开。会议由蒋晓萌董事长主持,全体九名董事亲自参加了会议;部分监事和高级管理人员列席了会议,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。会议通过了如下决议:
一、通过了2011年度总经理业务报告
表决结果:同意9票、反对0票、弃权0票。
二、通过了2011年年度报告及其摘要
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
三、通过了2011年度财务决算报告
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
四、通过了2011年度利润分配预案
经天健会计师事务所审计,2011年度公司归属于母公司股东的净利润268803858.08元,按母公司的本期净利润109774881.48元为基数,提取10%法定公积金10977488.15元。本年度可供分配的利润为257826369.93元,加年初未分配利润259763197.82元,本年度可供分配利润为 517589567.75 元。
公司2011年度拟进行现金分配,以2011年末股本344083828股为基数,每10股派发现金红利1.2元(含税)。2011年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
五、通过了对外担保的议案
董事会一致通过了该议案,同意以下各项对外担保事宜。
(一)对控股子公司的担保
1、对于控股子公司向金融机构借款提供担保,设定如下额度:
|
被担保单位 |
本次设定担保额度(万元) |
|
大冶尖峰水泥有限公司 |
30000 |
|
浙江尖峰药业有限公司 |
20000 |
|
金华市医药公司 |
2000 |
|
浙江尖峰国际贸易有限公司 |
1000 |
|
云南尖峰水泥有限公司 |
20000 |
|
总 计 |
73000 |
2、随着浙江尖峰国际贸易有限新增仓库投入运行,仓储业务量增加,成功引进了中国石化等大型企业的仓储业务,还成为大连商品交易所的PVC、PE期货交割仓库,此等业务需第三方提供担保。公司拟同意出具担保函,为浙江尖峰国际贸易有限公司的客户存放的货物提供相应的担保(详见公告临2012-007)。
(二)互保
同意与浙江凯恩特种材料股份有限公司实行额度5000万元的互相担保。在其履行相关程序后,公司将与其签订互保协议,期限为一年(详见公告临2012-008)。
并提请股东大会授权在上述额度内的担保由董事长根据实际情况分次执行。
表决结果:同意9票、反对0票、弃权0票。
本预案需报股东大会审议。
六、通过了投资报告
会议审议通过了该报告,批准了报告中提出的投资、技改和新产品开发等项目。
1、大冶尖峰水泥有限公司机修车间技改项目,计划投资220万元。
2、浙江尖峰药业有限公司滴眼液生产线技改项目,计划投资680万元。
3、浙江尖峰药业有限公司单独出资设立保健品销售公司,注册资本1000万元。
4、对浙江尖峰国际贸易有限公司增资,计划增资1000万元。
5、尖峰药业新产品开发。尖峰药业拟投入3900万元(按阶段成果分期支付)与中国药科大学及其医药化工研究所等相关方合作,进行抗肿瘤一类新药(DPT)的临床前研究。
6、出让北京勤益科技投资管理有限公司股权。
北京勤益科技投资管理有限公司注册资本4000万元,其中本公司出资475万元(占11.875%),公司拟以546.25万元出让该股权。
表决结果:同意9票、反对0票、弃权0票。
七、关于聘请公司2012年度审计机构的议案
同意聘请天健会计师事务所有限公司为公司2012年度财务报告及其他审计业务的审计机构。审计费用参照有关规定,以业务量为衡量标准,请股东大会授权董事会与该所谈判为准。审计期间的食、宿等费用由公司承担。
表决结果:同意9票、反对0票、弃权0票。
本预案需报股东大会审议。
八、通过了2011年度董事会报告
表决结果:同意9票、反对0票、弃权0票。
该议案需提交股东大会审议。
九、通过了召开2011年度股东大会方案
(一)会议召开时间:2012年5月8日上午9:00。
(二)会议召开地点:浙江省金华市婺江东路88号尖峰大厦。
(三)会议主要议程:
1、审议2011年度董事会工作报告;
2、审议2011年度监事会工作报告;
3、审议2011年度财务决算报告;
4、审议2011年度利润分配方案;
5、审议聘请2012年度审计机构的方案;
6、审议对外担保的方案;
7、审议2011年年度报告及其摘要。
(四)出席对象
1、凡2012年5月3日(股权登记日)交易结束后在中国证券中央登记结算公司上海分公司登记在册的本公司股东及其授权委托人均可出席。
2、本公司董事、监事及高级管理人员。
(五)会议登记办法
1、法人股股东持单位证明、法人代表委托书和出席人身份证登记;社会公众股股东凭股东帐户卡、本人身份证登记。股东可以信函或传真方式进行预登记。
2、预登记时间:2012年5月7日。
3、登记地点:浙江省金华市婺江东路88号尖峰大厦。
表决结果:同意9票、反对0票、弃权0票。
特此公告
二〇一二年四月六日
浙江尖峰集团股份有限公司董事会
附件 授权委托书样:
兹全权委托 先生(女士)代表本人出席浙江尖峰集团股份有限公司2011年年度股东大会,并依照委托人指示就各议案进行投票,如果委托人没有指示则由受托人自行投票。
委托人签名:
委托人股东帐号: 委托人身份证号码:
委托人持股数:
受托人签名: 受托人身份证号码:
有效期:
委托日期 年 月 日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11